Last reviewed · How we verify
Neo-Synalar Cream
Neo-Synalar Cream is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin.
Neo-Synalar Cream is a topical corticosteroid that reduces inflammation and suppresses immune responses in the skin. Used for Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis).
At a glance
| Generic name | Neo-Synalar Cream |
|---|---|
| Also known as | NS 0.5%(0.35% neomycin base)/ FA 0.025% Cream |
| Sponsor | Noah Rosenberg, MD |
| Drug class | Topical corticosteroid |
| Target | Glucocorticoid receptor |
| Modality | Small molecule |
| Therapeutic area | Dermatology |
| Phase | FDA-approved |
Mechanism of action
The cream contains a potent corticosteroid (fluocinolone acetonide) that binds to glucocorticoid receptors in skin cells, suppressing inflammatory cytokine production and reducing vasodilation, edema, and pruritus. This makes it effective for inflammatory and allergic skin conditions where localized anti-inflammatory action is needed.
Approved indications
- Inflammatory and pruritic dermatoses responsive to topical corticosteroids (e.g., eczema, psoriasis, dermatitis)
Common side effects
- Skin atrophy
- Striae
- Telangiectasia
- Local irritation or burning
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Neo-Synalar Cream CI brief — competitive landscape report
- Neo-Synalar Cream updates RSS · CI watch RSS
- Noah Rosenberg, MD portfolio CI